New study aims to decode PTCL by genetic subtype
NCT ID NCT07657572
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goal is to better understand the disease and improve future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict which treatments work best for different PTCL subtypes.
- What could go wrong
- This is an observational registry, not a treatment trial. It may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug spare healthy cells while killing lymphoma?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
- New hope for tough lymphoma: TR115 faces off against standard care
- Massive T-Cell lymphoma database aims to unlock new insights